LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer ...
Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...
Zacks Investment Research on MSN
LLY trading above 50 & 200-day SMAs for 2 months: How to play the stock
Eli Lilly and Company’s LLY stock has been consistently trading above its 50-day and 200-day simple moving averages (SMAs) ...
ToolGen Inc. (KOSDAQ: 199800), a leading genome editing company based in Korea, announced today that it has entered into a strategic cross-license agreement with GenEditBio Limited ("GenEditBio"), a ...
Abivax stock skyrocketed in July after the company announced overwhelmingly positive topline results from its Phase 3 ...
An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...
Eli Lilly has advanced in the triple-digits over three years, thanks to its weight loss drug portfolio. The following two biotech companies, due to the potential of their late-stage candidates, also ...
Forbes contributors publish independent expert analyses and insights. Peter Cohan, a Boston-based senior contributor, covers stocks. Eli Lilly achieved a $1 trillion market cap, a healthcare first, ...
Hosted on MSN
Is Eli Lilly a Millionaire Maker?
Eli Lilly just agreed to lower the price of its blockbuster GLP-1 weight loss drug. More than half of the company's revenue comes from just two weight loss drugs. Wall Street may be pricing in too ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback